Immunomedics (NASDAQ:IMMU) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06), Fidelity Earnings reports. Immunomedics had a negative return on equity of 124.54% and a negative net margin of 12,701.21%. During the same quarter in the prior year, the firm posted ($0.97) earnings per share.
Shares of Immunomedics stock traded up $0.52 on Wednesday, hitting $24.24. The stock had a trading volume of 1,620,000 shares, compared to its average volume of 2,132,922. Immunomedics has a twelve month low of $8.68 and a twelve month high of $27.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 14.83 and a quick ratio of 14.83. The company has a market capitalization of $4.66 billion, a P/E ratio of -23.53 and a beta of 1.93.
A number of research analysts have recently commented on IMMU shares. Goldman Sachs Group started coverage on shares of Immunomedics in a report on Monday, September 17th. They issued a “buy” rating and a $36.00 target price for the company. Guggenheim started coverage on shares of Immunomedics in a report on Tuesday, September 18th. They issued a “buy” rating and a $33.00 target price for the company. Wells Fargo & Co increased their target price on shares of Immunomedics from $31.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, October 17th. TheStreet downgraded Immunomedics from a “c-” rating to a “d+” rating in a research note on Tuesday, September 11th. Finally, BidaskClub downgraded Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, September 15th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $38.00.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/07/immunomedics-immu-posts-earnings-results-misses-estimates-by-0-06-eps.html.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Further Reading: Consumer behavior in bull markets
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.